Generic selectors
Exact matches only
Search in title
Search in content

No products in the cart.

Immusmol: the Small Molecule Antibody Company

Founded in 2012 by Alban Bessede, PhD – Immunologist, Immusmol aims to become a natural choice for small molecule antibodies development. Supported by public institutions including BPI, Conseil Régional Nouvelle Aquitaine, as well as by its Co-founder Associate – SCHIEVER, Immusmol is established in Bordeaux, France.


Our focus: antibodies targeting small molecules

ImmuSmol stands for “immunoglobulins [antibodies] against small molecules”. While traditional antibodies only recognize large molecules such as proteins, ImmuSmol designs and develops antibodies capable of targeting low molecular weight entities (<900 Da).

Amino acids, lipids, saccharids, toxins, drugs, … virtually any small molecule can thus be addressed with high affinity and specificity. Fully compatible with existing antibody-based technologies, small molecule antibodies are opening a whole new set of possibilities in research, diagnostics and therapy.

Three core applications

  • Research antibodies – ImmuSmol sells validated primary antibodies, for small molecule detection and visualization in cells and tissues.
  • Custom services – ImmuSmol offers to raise antibodies targeting small molecules for research, diagnostic and therapeutic applications.
  • Diagnostics & Therapy – Three personalized medicine programs based on proprietary small molecule antibodies are currently under development.